Raghu Kalluri, Professor and Chairman of Department of Cancer Biology at MD Anderson Cancer Center, shared a post on LinkedIn:
“Hot off the press from Kalluri Lab: We identify CDK8 as a resistance mechanism across several Kras inhibitors, including daraxonrasib.
Targeting CDK8 alone can overcome resistance and sensitize tumors to checkpoint immunotherapy with curative outcomes in models of pancreaticcancer.”
Title: CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC
Authors: Kathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li, Anaïs M Comptdaer, Amari M Sockwell, Sami J Morse, Patience J Kelly, Sarah I Patel, Michelle L Kirtley, Barbara A Moreno Diaz, Hengyu Lyu, David H Peng, Sima Khazaei, Aislyn Schalck, Xunian Zhou, Hikaru Sugimoto, Aaron A Bickert, Lakshmi Kavitha Sthanam, Meagan R Taylor, Shreyasee V Kumbhar, Kent A Arian, Yasaman Barekatain, Francesca Paradiso, Paola A Guerrero, Vincent Bernard, Navid Sobhani, Alondra N Camacho-Acevedo, Kiara E Bornes, Phuong Thao Tran, Anirban Maitra, Timothy P Hefferna, Raghu Kalluri
Read The Full Article
